ICLR vs MEDP
ICON Public Limited Company vs Medpace — AI-powered side-by-side comparison
ICLR
ICON Public Limited Company
68
Buy
VS
| Metric | ICLR | MEDP |
|---|
| AI Score |
68
|
67
|
| Price |
$163.01
|
$578.86
|
| P/E Ratio |
39.04×
|
33.46×
|
| ROE |
2.5%
|
98.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
21.8%
|
28.8%
|
| Debt / Equity |
0.37×
|
0.28×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.0
|
48.8
|
| Beta |
1.203
|
1.151
|
| Expected Upside |
+17.5%
|
+7.1%
|
AI Committee View
Current Innellis committee reasoning for ICLR versus MEDP.
ICLR leads by 1 points.
ICLR scores 68/100 (Buy) versus MEDP at 67/100 (Buy).
ICLR Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
MEDP Committee View
67% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is p/e of 33.1 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.1 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical